Deerfield Commits $36 Million to Advance Dracen's Novel Immuno-Metabolism Pipeline

Thursday, March 22, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK and BALTIMORE, March 22, 2018 /PRNewswire/ -- Deerfield Management announced today

that it has committed $36 million of a $40 million Series A investment to advance Dracen Pharmaceuticals, Inc.'s novel immuno-metabolism pipeline.  Dracen, a private company developing proprietary
anti-cancer drugs discovered at the Johns Hopkins University and the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague), will use this financing to progress its programs into clinical trials for patients suffering from cancer.

Dracen will develop its platform of novel glutamine antagonists by building upon the immuno-metabolism effects demonstrated in preclinical cancer models.  Immuno-metabolism is the convergence of cancer metabolism and immuno-oncology whereby agents disrupt the energy sources required to keep tumors alive while simultaneously inducing the patient's own immune system to fight cancer.  Dracen intends to develop its glutamine antagonists both in single-agent settings as well as in combination with immune checkpoint inhibitors such as anti-PD-1 and anti-PD-L1.

"We are pleased to partner with Dracen and its founders from Johns Hopkins University," said Jonathan S. Leff, a Partner with Deerfield Management.  "We see great potential for Dracen's approach to deliver improved outcomes for cancer patients and potentially extend the benefits of immuno-oncology therapies."

"We are excited to partner with Deerfield to advance our immuno-metabolism pipeline" remarked Thomas M. Estok, Chief Executive Officer of Dracen Pharmaceuticals.  "Deerfield's engagement in our efforts helps bring us closer to an important potential step forward in the treatment of cancer." 

About Dracen Pharmaceuticals

Dracen Pharmaceuticals, Inc. is a privately-funded biotech company developing proprietary glutamine antagonists discovered at the Johns Hopkins University and the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague).  Dracen was founded by Johns Hopkins University professors Barbara Slusher, MAS/PhD; Jonathan Powell, MD/PhD; and Rana Rais, PhD; together with their IOCB Prague collaborator Pavel Majer, PhD to develop the novel glutamine antagonists for the treatment of cancers as well as autoimmune and inflammatory diseases.

About Deerfield

Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.

For more information, please visit www.deerfield.com

Contact

Deerfield Management CompanyKaren Heidelberger, 212-551-1600karenh@deerfield.com

Cision View original content:http://www.prnewswire.com/news-releases/deerfield-commits-36-million-to-advance-dracens-novel-immuno-metabolism-pipeline-300617886.html

SOURCE Deerfield Management Company

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store